AMENDMENTS TO THE CLAIMS

Claims 1-6 and 11-29 are cancelled. Claims 7-10 were previously withdrawn. Claims 30-46 are newly added. Support for the amendments can be found throughout the specification and claims as originally filed. This listing of claims will replace all prior versions, and listings of claims, in the application.

Listing of Claims:

1. (Canceled)

2. (Canceled)

3. (Canceled).

4. (Canceled)

5. (Canceled)

6. (Canceled)

7. (Withdrawn) A method for producing the compound of formula I, comprising the steps of:

(a) in the presence of copper powder and anhydrous alkaline earth metal carbonate, reacting the compound of formula II and the compound of formula III at 160-200° C., thereby producing the compound of formula Ia;



wherein

R_1 is methyl, ethyl or trifluoromethyl at position 3, 4, 5 or 6,

R_3 is --OCH_3, --SCH_3, --OC_2H_5 or --SC_2H_5 at position 2, 3 or 4, and

X is Cl, Br or I;

(b) reacting the compound of formula Ia and BBr_3 in an inert solvent at -10° C. to 15° C., thereby producing the compound of formula I:



wherein, R_1 and R_3 are defined as above, and R_2 is -OH or -SH.

8. (Withdrawn) A method for producing a pharmaceutical composition, comprising the steps of mixing the compound of formula I or the pharmaceutically acceptable salts thereof according to claim 1 with a pharmaceutically acceptable carrier to produce a pharmaceutical composition comprising 0.01-99 wt % of the compound of formula I, on the basis of the total weight.

9. (Withdrawn) Use of the compound of formula I or the pharmaceutically acceptable salts thereof according to claim 1 in the manufacture of a medicament for preventing fibrosis.

10. (Withdrawn) A method for treating fibrosis diseases, comprising administrating a safe and effective amount of the compound of formula I or the pharmaceutically acceptable salts thereof according to claim 1 to a subject in need thereof.

11. (Canceled)

12. (Canceled)

13. (Canceled).

14. (Canceled)

15. (Canceled)

16. (Canceled)

17. (Canceled)

18. (Canceled)

19. (Canceled)

20. (Canceled)

21. (Canceled).

22. (Canceled)

23. (Canceled)

24. (Canceled)

25. (Canceled)

26. (Canceled)

27. (Canceled)

28. (Canceled)

29. (Canceled)

30. (New) A pharmaceutical composition comprising:

(a) a therapeutically-effective amount of the compound of formula I or a pharmaceutically acceptable salts thereof, wherein



Formula (I)

wherein R_1 is methyl, and R_2 is hydroxyl.

(b) a pharmaceutically-acceptable excipient.

31. (New) The pharmaceutical composition of claim 30, wherein R_1 is methyl at position 5, and R_2 is hydroxyl at position 4.

32. (New) The pharmaceutical composition of claim 30, wherein the composition comprises 0.01-99% of the compound of formula I or the pharmaceutically acceptable salts thereof, on the basis of the total weight.

33. (New) The pharmaceutical composition of claim 30, wherein composition is formulated as a tablet, capsule, ampule or pill.

34. (New) The pharmaceutical composition of claim 30, wherein the pharmaceutical composition is formulated for oral, intravenous, intramuscular or subcutaneous administration.

35. (New) The pharmaceutical composition of claim 30, wherein the pharmaceutical composition is formulated for oral administration.

36. (New) The pharmaceutical composition of claim 30, wherein the pharmaceutical composition is formulated for external administration.

37. (New) The pharmaceutical composition of claim 30, wherein the composition is formulated as an ointment, gel, or drug-containing rubber cement.

38. (New) The pharmaceutical composition of claim 30, wherein the pharmaceutical composition is formulated for parenteral administration.

39. (New) The pharmaceutical composition of claim 30, wherein the composition comprises 0.1-90% of the compound of formula I or the pharmaceutically acceptable salts thereof, on the basis of the total weight.

40. (New) The pharmaceutical composition of claim 30, wherein the pharmaceutical is formulated for slow release.

41. (New) The pharmaceutical composition of claim 30, wherein the excipient is starch, lactin, dicalcium phosphate, microcrystalline cellulose, sucrose, white bole or combinations thereof.

42. (New) The pharmaceutical composition of claim 30, wherein the excipient is sterile water, polyethylene glycol, a nonionic surfactant, edible oil or combinations thereof.

43. (New) The pharmaceutical composition of claim 30, further comprising an adjuvant.

44. (New) The pharmaceutical composition of claim 30, wherein the pharmaceutical composition is formulated for administration in 2-4 separated dosages per day.

45. (New) The pharmaceutical composition of claim 30, further comprising a flavoring agent, colorant, preservative, antioxidant, or combinations thereof.

46. (New) The pharmaceutical composition of claim 30, further comprising vitamin E, vitamin C, butylated hydroxytoluene (BHT), butylated hydroxy anisole (BHA) or combinations thereof.